This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

BAY 77-1931 Long-term Extension From Phase II Study

This study has been completed.
Information provided by:
Bayer Identifier:
First received: October 8, 2008
Last updated: January 21, 2013
Last verified: January 2013
A long-term study of BAY77-1931 (lanthanum carbonate) for hyperphosphatemia in patients undergoing hemodialysis

Condition Intervention Phase
Hyperphosphatemia Drug: BAY 77-1931 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Long-term, Open Label Extension, Non-controlled Study to Assess the Efficacy and Safety of BAY 77-1931 (Lanthanum Carbonate) for Hyperphosphatemia in Patients Undergoing Hemodialysis

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Changes in pre-dialysis serum phosphate levels [ Time Frame: Every 4 weeks ]

Secondary Outcome Measures:
  • Achievement rate of the target predialysis serum phosphate levels (3.5 mg/dL and 5.5 mg/dL) [ Time Frame: Every 4 weeks ]
  • Changes in corrected serum calcium level [ Time Frame: Every 4 weeks ]
  • Changes in the product of serum calcium and phosphate [ Time Frame: Every 4 weeks ]
  • Changes in serum intact-PHT levels [ Time Frame: Every 4 weeks ]
  • Changes in bone metabolism markers [ Time Frame: Every 4 weeks ]

Enrollment: 145
Study Start Date: January 2005
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Drug: BAY 77-1931
Lanthanum Carbonate (BAY 77-1931)


Ages Eligible for Study:   20 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Undergoing hemodialysis 3 times per week for chronic renal failure for the previous 3 consecutive months at least

Exclusion Criteria:

  • Pre-dialysis serum phosphate levels of 10.0mg/dL during the washout period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00769496

Toyohashi, Aichi, Japan, 441-8023
Yatomi, Aichi, Japan, 498-0006
Kashiwa, Chiba, Japan, 277-0084
Narita, Chiba, Japan, 286-0041
Sakura, Chiba, Japan, 285-0846
Asahikawa, Hokkaido, Japan, 070-0030
Suita, Osaka, Japan, 564-0053
Chiba, Japan, 261-0011
Hiroshima, Japan, 730-0811
Kochi, Japan, 780-0066
Kochi, Japan, 780-8040
Kochi, Japan, 781-5103
Okayama, Japan, 701-0202
Tokushima, Japan, 770-0011
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Therapeutic Area Head, Bayer Yakuhin Ltd. Identifier: NCT00769496     History of Changes
Other Study ID Numbers: 11551
Study First Received: October 8, 2008
Last Updated: January 21, 2013

Additional relevant MeSH terms:
Phosphorus Metabolism Disorders
Metabolic Diseases processed this record on September 19, 2017